MAPK3
-
Official Full Name
MAPK3 mitogen-activated protein kinase 3
-
Synonyms
MAPK3; mitogen-activated protein kinase 3; PRKM3; ERK1; p44erk1; p44mapk; MAPK 1; MAP kinase 1; MAP kinase 3; MAP kinase isoform p44; insulin-stimulated MAP2 kinase; mitogen-activated protein kinase 1; extracellular signal-related kinase 1; extracellular signal-regulated kinase 1; microtubule-associated protein 2 kinase; ERT2; ERK-1; P44ERK1; P44MAPK; HS44KDAP; HUMKER1A; p44-ERK1; p44-MAPK; MGC20180;
- Recombinant Proteins
- Cell & Tissue Lysates
- Protein Pre-coupled Magnetic Beads
- Human
- Mouse
- Rat
- Zebrafish
- E. coli
- E.coli
- HEK293
- HEK293T
- Mammalian Cell
- Mammalian cells
- C
- Myc
- DDK
- Flag
- GST
- His
- His (Fc)
- Avi
- His|MBP
- N/A
- No tag
- Involved Pathway
- Protein Function
- Interacting Protein
- MAPK3 Related Articles
- MAPK3 Related Research Area
- MAPK3 Related Signal Pathway
MAPK3 involved in several pathways and played different roles in them. We selected most pathways MAPK3 participated on our site, such as MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, which may be useful for your reference. Also, other proteins which involved in the same pathway with MAPK3 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|---|
MAPK signaling pathway | IL1R1;IL1A;CACNA1H;MAP4K1;FGFR4;FGF19;MAP2K5;TP53;ATF4 |
ErbB signaling pathway | RPS6KB2;PLCG2;GRB2;CDKN1BA;PAK2B;PAK2;SHC1;CAMK2B;RAF1B |
Ras signaling pathway | IGF1R;PLA2G6;REL;STK4;FGF9;GNGT1;RASGRF2;FGF11;RIN1 |
Rap signaling pathway | BRAF;SKAP1;KIT;FGF4;MAGI1;KRAS;MAPK3;VEGFA;HRAS |
cGMP-PKG signaling pathway | NFATC1;VDAC2;VDAC1;PLCB2;PPP3CB;AGTR1A;GTF2I;INSR;MEF2D |
cAMP signaling pathway | CNGA1;GRIN3A;PTGER2;VAV1;AMH;CALML3;CAMK2G;RAC1;PRKACB |
Chemokine signaling pathway | PTK2;NFKBIB;WASL;CXCL2;CCL6;RHOA;GNG13;ROCK2;BRAF |
HIF- signaling pathway | NOS3;PIK3R2;ENO1;PDK1;PIK3R5;IFNG;FLT1;ERBB2;HKDC1 |
FoxO signaling pathway | TGFB1;CCND2;IRS1;RAF1;MAP2K2A;PLK4;INSB;TGFB2;GADD45BA |
Sphingolipid signaling pathway | PLCB1;RELA;ACER1;ROCK2;PPP2R2A;PLCB3;SGPL1;MAP2K2;PPP2R2D |
Phospholipase D signaling pathway | PTK2B;PDGFRB;LPAR4;GRM3;MS4A2;KIT;IL-8;CXCR2;SPHK1 |
Oocyte meiosis | CPEB2;YWHAE2;ADCY1A;IGF1RB;PLCZ1;PPP2R5A;CAMK2D2;CCNB1;CALM |
mTOR signaling pathway | INSB;PTENA;RPS6KA1;PRKAA1;CAB39L;AKT2;RPS6KB1B;PIK3R3;PIK3R5 |
PIK-Akt signaling pathway | INSR;PHLPP2;MDM2;ITGA2B;PKN3;GNG2;FLT1;ITGA2;Ifna15 |
Adrenergic signaling in cardiomyocytes | CREB3L3;KCNQ1;PIK3R3;MAPK12A;PRKACG;MYL2B;AGTR2;ATF6B;RAPGEF3 |
Vascular smooth muscle contraction | PLA2G4C;CALCRLA;ADRA1BB;MLCK2;PLA2G4F;PRKCG;MYLK4;PLA2G12B;NPR1 |
Dorso-ventral axis formation | KRAS;PIWIL2;NOTCH4;NOTCH3;ETV6;NOTCH2;SPIRE2;NOTCH1;GRB2B |
TGF-beta signaling pathway | SMAD6;TGFBR1A;LTBP1;BAMBI;TGFB3;INHBA;BMP7;SMAD4;ACVR1C |
Axon guidance | COL9A1A;MYL12A;NFATC3;ARHGEF12;ARPC4;NCAN;CDK5R1B;Plxna2;FRS3 |
VEGF signaling pathway | BADB;SPHK1;MAPKAPK2A;PLCG1;PLCG2;PLA2G4C;RAC2;SRC;PPP3CB |
Osteoclast differentiation | MAPK3;FCGR1;PPP3CB;AKT1;CYBA;cgr2b;MAPK9;TGFB2;CSF1 |
Focal adhesion | ELK1;MLCK2;PDGFC;PTK6;TNK2;COL2A1B;BCL2;ACTB;ITGA7 |
Adherens junction | TCF7L1A;SSX2IP;FER;SMAD3A;AASS;ACTB;INSRA;WASL;FGFR1 |
Gap junction | PRKACAB;CDK1;GNAI2B;RAF1A;PDGFRA;TJP1;PLCB2;PDGFAB;TUBA3B |
Signaling pathways regulating pluripotency of stem cells | ESRRB;NRAS;ACVR2A;INHBA;SMAD4;AKT1;WNT10B;PCGF1;MAPK12 |
Platelet activation | AKT1;PIK3CG;LCP2;GP1BB;ARHGAP35;GNAI2;MYL12B;PIK3CA;FCER1G |
Toll-like receptor signaling pathway | IFNA16;PIK3CA;CCL4;TICAM2;NFKBIA;MAP2K2;MAPK11;IFNA8;IL1B |
NOD-like receptor signaling pathway | NLRC4;NFKBIA;IL6;IL18;NLRP3;CARD8;PSTPIP1A;NFKBIAB;CASP5 |
Natural killer cell mediated cytotoxicity | HLA-G;Raet1c;FCGR3A;CD247;PIK3CG;PIK3R3;PIK3R2;PPP3CC;KLRC3 |
T cell receptor signaling pathway | PLCG1;AKT1;AKT2;VAV2;PRKCQ;PAK1;DEF6A;NFKBIE;PAK2 |
B cell receptor signaling pathway | PDK2;MALT1;BLNK;SYK;LCP2A;LIME1;PIK3R3;CD79A;PPP3CB |
Fc epsilon RI signaling pathway | PLA2G4F;AKT1;LAT;IL13;BTK;PIK3R5;MAP2K3;PIK3CB;FCER1G |
Fc gamma R-mediated phagocytosis | PLD2;PIK3R2;RPS6KB1;WASF3;FCGR2A;ARF6;FCGR1;MAPK1;VAV2 |
TNF signaling pathway | MAPK10;MMP14;VCAM1;RELA;CREB3L2;RPS6KA5;MAP2K6;BCL3;Ccl12 |
Circadian entrainment | MAPK1;GNGT1;GNG10;GRIN2D;ITPR1;GNG8;CALML5;RYR3;GNG12 |
Long-term potentiation | RPS6KA3;PPP1CB;PRKCB;CALM3;CAMK2A;RAF1;MAP2K2;ITPR3;PRKACG |
Neurotrophin signaling pathway | PSEN2;NTF4;MAPK3;MAP2K1;PRKCD;NFKBIE;ARHGDIG;RAP1A;KIDINS220 |
Retrograde endocannabinoid signaling | SLC17A7;GNAQ;GRIA4;GRIA3;PRKCA;GRIA1;SLC17A6;NAPEPLD;GNAO1 |
Glutamatergic synapse | PLA2G4C;SLC38A2;GRM3;GRIN2D;PRKACA;GRM4;GNG2;GRIN2A;GRM2 |
Cholinergic synapse | AKT2;CHRM2;CHRM5;KCNJ12;CAMK2D;PRKACG;GNG8;KCNJ2;GNB3 |
Serotonergic synapse | GNB1;HTR5A;HTR1F;HRAS;HTR3A;PRKCB;HTR2B;ITPR1;GNG12 |
Long-term depression | GNAI3;IGF1;GRIA2;GRIA1;PRKCG;BRAF;PLCB4;ARAF;ITPR1 |
Regulation of actin cytoskeleton | PDGFB;RAF1B;FGF11;RAC1B;ITGAL;PDGFAB;FGF16;ARHGAP35;PAK6 |
Insulin signaling pathway | HK2;GSK3B;NRAS;ACACA;BAD;PRKACG;PRKAA1;PIK3R3;GRB2A |
GnRH signaling pathway | GRB2B;CALML3;ITPR1;CALM3B;MAP3K2;GNRH1;CAMK2G;HRASA;MAP2K3 |
Progesterone-mediated oocyte maturation | CDC16;PIK3R5;PRKACAB;HSP90AA1.1;GNAI2;RPS6KA2;MAPK3;PIK3R2;PRKACA |
Estrogen signaling pathway | GABBR2;PIK3CG;GNAI2;PRKACA;KCNJ9;MAP2K2;PLCB4;KCNJ3;SHC2 |
Melanogenesis | TCF7L1A;WNT16;CALM2A;POMCA;WNT9A;GNAI1;EDNRB2;CAMK2D;FZD2 |
Prolactin signaling pathway | RELA;STAT3;INS1;TH;MAP2K1;SHC4;LHCGR;PIK3R3;SHC1 |
Thyroid hormone signaling pathway | ATP1A1;GSK3B;MDM2;PRKACA;ATP1A4;ITGB3;PRKCA;MTOR;NOTCH1 |
Oxytocin signaling pathway | CAMK2A;CAMKK2;RYR3;PPP1CC;CACNB2;PRKCA;GUCY1B3;CAMK2B;PPP3CB |
Type II diabetes mellitus | SOCS2;MAPK3;HK1;PRKCD;INSR;PKM;MTOR;PIK3CA;INS1 |
Aldosterone-regulated sodium reabsorption | PIK3CD;PRKCB;ATP1A1;NEDD4L;ATP1A3;PRKCA;PIK3R5;PIK3R1;FXYD2 |
Alzheimers disease | ATP2A2;IDE;ATF6;RYR3;NDUFB9;UQCRH;CALM2;TNFRSF1A;ATP5O |
Prion diseases | NCAM2;STIP1;C1QA;HSPA1A;PRKACG;Hc;C9;PRNP;C7 |
Alcoholism | GNG13;HIST1H2BJ;PPP1CB;HIST1H2BB;HDAC2;HDAC3;PDYN;MAPK1;H2AFJ |
Shigellosis | FBXW11;CTTN;ATG5;NFKBIB;RAC1;ABL1;IL-8;CD44;ROCK2 |
Salmonella infection | KLC1A;MAPK3;RAC1A;KLC1;NOS2A;IFNG1-2;CD14;PFN2L;MAPK8B |
Pertussis | MAPK9;C4BPA;ITGB1;CXCL5;C1S;Il23a;TNF;C4BPB;NFKB1 |
Leishmaniasis | PRKCB;MAPK1;IL4;MAPK11;IL12A;HLA-DRB5;HLA-DRB3;HLA-DQA2;HLA-DMA |
Chagas disease (American trypanosomiasis) | FOS;GNAO1;PPP2R2A;CD3D;IL10;CXCL8;TLR9;TGFB2;RELA |
Toxoplasmosis | IRAK1;NFKB1;MAPK3;GNAI1;PIK3R3;IRGM1;IFNG;TGFB2;Toxoplasma Gondii Profilin Family Protein |
Tuberculosis | ARHGEF12;IL12B;CAMK2A;IL18;TGFB3;CAP18;ATP6AP1;IL1A;HLA-DQB1 |
Hepatitis C | AKT2;IRF1;PIAS1;PIK3CB;Ifna15;CLDN6;BRAF;TNFRSF1A;IFNA17 |
Hepatitis B | IL-8;STAT2;CCNA1;EP300;PRKCG;CASP9;MAVS;NFKB1;IKBKB |
Influenza A | IFNA14;TNFRSF10D;HLA-DRB4;IFNGR1;IFNG;IFNA5;MAPK8;MAP2K4;PRSS1 |
Pathways in cancer | DAPK2;CBL;GNG13;PLCB4;HSP90B1;PLEKHG5;RXRB;LAMA4;EGLN3 |
Viral carcinogenesis | HDAC8;LYN;TTC6;C3;UBR4;HDAC4;HIST3H2BB-PS;DNAJA3;HDAC10 |
Proteoglycans in cancer | RPS6KB1;PIK3R3;CD63;PPP1CC;PIK3CD;PPP1R12A;MAPK3;WNT3;PRKACA |
Colorectal cancer | MSH3;RAF1;TGFB2;ARAF;MAP2K1;CYCS;PIK3CD;BRAF;MLH1 |
Renal cell carcinoma | EGLN2;PIK3CD;RAP1B;FH;TGFB2;TCEB2;RAF1;PTPN11;RAP1A |
Pancreatic cancer | AKT2;TGFB3;MAPK8;ARHGEF6;BRAF;BRCA2;RAC3;RALB;NFKB1 |
Endometrial cancer | TCF7L2;MAP2K1;PIK3CA;MAPK1;PIK3R3;AXIN1;CCND1;ERBB2;ARAF |
Glioma | CALM3;SHC3;PIK3CA;PRKCB;PDGFA;SOS1;TRP53;SHC1;CALM4 |
Prostate cancer | FOXO1;RB1;RAF1;NDRG1;PIK3R2;SRD5A2;CREB3L3;NFKB1;AKT2 |
Thyroid cancer | NCOA4;NTRK1;CCDC6;NRAS;RXRA;LEF1;KRAS;PAX8;HRAS |
Melanoma | PIK3CG;FGF2;PIK3R5;FGF19;MAPK1;FGF8;FGF13;PIK3R3;NRAS |
Bladder cancer | TRP53;FGFR3;E2F2;MMP2;MAP2K1;MMP1;THBS1;CDKN2A;TYMP |
Chronic myeloid leukemia | NFKB1;PTPN11;CBLC;IKBKB;HDAC1;NRAS;MAP2K2;PIK3R5;STAT5B |
Acute myeloid leukemia | AKT3;RARA;MAPK3;RUNX1;JUP;IKBKG;RPS6KB1;MAPK1;STAT3 |
Non-small cell lung cancer | RXRA;MAPK3;RXRG;PIK3R5;MAPK1;BRAF;HRAS;PRKCB;PRKCA |
Central carbon metabolism in cancer | MET;IDH1;MAPK1;LDHA;PDGFRA;PIK3R3;KIT;HKDC1;SLC2A2 |
Choline metabolism in cancer | CHKA;PDGFRA;MAPK3;MAP2K2;RALGDS;PIK3R2;Pdgfa&Pdgfb;PLCG1;PIK3R3 |
MAPK3 has several biochemical functions, for example, ATP binding, MAP kinase activity, phosphatase binding. Some of the functions are cooperated with other proteins, some of the functions could acted by MAPK3 itself. We selected most functions MAPK3 had, and list some proteins which have the same functions with MAPK3. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
ATP binding | ACTR8;RIOK3;EPHB2B;FLT1;CCT5;TSSK1;DDX53;KATNA1;UBA1 |
MAP kinase activity | MAPK3;MAPK14B;MAPK14;MAPK8B;MAPK1;MAPK13;MAPK14A;NLK;MAPK11 |
phosphatase binding | DYSFIP1;SLC9A3R1;CRY2;SYTL2;DLG1L;PPP1R21;SMAD3;CHCHD3;PPP1R26 |
phosphotyrosine binding | MAPK3;FGR;STAP1;PTPN3;GRB2;CBL;SHC1;CBLB;SAMSN1 |
protein binding | ZBP1;USP44;NAP1L1;CCL3;RCOR1;PBXIP1;PPP2R3A;FAM122A;DSCAM |
scaffold protein binding | KRT15;NOS3;CACNA1H;GRIN2A;CRIPT;DLG4;SHANK1;SHANK3;SRC |
MAPK3 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with MAPK3 here. Most of them are supplied by our site. Hope this information will be useful for your research of MAPK3.
DUSP1; PTPRJ; MAPK14; DHPS; Ptprr
- Q&As
- Reviews
Q&As (7)
Ask a questionDysregulation of MAPK3 signaling has been implicated in the pathogenesis of several diseases. Aberrant activation of MAPK3 is associated with cancer development and progression, as it promotes cell proliferation and survival. MAPK3 signaling is also involved in cardiovascular diseases, contributing to vascular remodeling and hypertrophy. In neurodegenerative diseases, dysregulated MAPK3 activity contributes to neuronal dysfunction and apoptosis.
Future research in MAPK3 aims to elucidate the intricate signaling network and identify novel regulatory mechanisms. Understanding the crosstalk between MAPK3 and other signaling pathways will be crucial for developing targeted therapies. Additionally, exploring the role of MAPK3 isoforms in different cellular contexts and disease states will provide valuable insights. Furthermore, the development of more specific and potent inhibitors with reduced toxicity profiles is a focus for future therapeutic interventions.
MAPK3, also known as ERK1 (Extracellular Signal-Regulated Kinase 1), is a serine/threonine kinase involved in cell signaling pathways. It consists of 379 amino acids and exhibits a conserved catalytic domain. MAPK3 plays a crucial role in regulating cell proliferation, differentiation, and survival by phosphorylating downstream targets such as transcription factors and other kinases.
MAPK3 signaling exerts its effects through phosphorylation of downstream targets. It phosphorylates various transcription factors, including ELK1 and c-Fos, leading to changes in gene expression. MAPK3 also phosphorylates other kinases, such as p90RSK, which further propagate the signal to regulate cellular processes like cell cycle progression, apoptosis, and differentiation.
One challenge is the potential for off-target effects when targeting MAPK3, as it is involved in multiple signaling pathways. Additionally, resistance to MAPK3 inhibitors can emerge due to compensatory signaling mechanisms and genetic alterations. Another challenge lies in achieving selective inhibition of specific MAPK3 isoforms without affecting other closely related kinases.
The activity of MAPK3 is tightly regulated by various mechanisms. Activation of MAPK3 involves dual phosphorylation of threonine and tyrosine residues by upstream kinases. Conversely, dephosphorylation by phosphatases can inactivate MAPK3. Additionally, scaffolding proteins and interacting partners can modulate its activity by facilitating or inhibiting its phosphorylation or by regulating its subcellular localization.
Inhibition of MAPK3 activity or downstream effectors represents a potential therapeutic approach. Small molecule inhibitors targeting MAPK3 kinase activity, such as U0126 and PD98059, have been developed. Monoclonal antibodies against MAPK3 or its downstream effectors are also being investigated. Combination therapies targeting multiple components of the MAPK3 signaling pathway are being explored to enhance efficacy and overcome resistance.
Customer Reviews (3)
Write a reviewExemplary precision and unblemished dependability render it my most cherished research ally.
Presenting exceptional reliability and stability, the experimental reagent establishes a robust foundation for my experiments.
Exquisitely crafted packaging design adds convenience to the usage of this protein reagent and exudes a sense of sophistication.
Ask a Question for All MAPK3 Products
Required fields are marked with *
My Review for All MAPK3 Products
Required fields are marked with *